220 related articles for article (PubMed ID: 15192276)
1. CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan.
Konishi I; Horiike N; Hiasa Y; Michitaka K; Onji M
Intervirology; 2004; 47(2):114-20. PubMed ID: 15192276
[TBL] [Abstract][Full Text] [Related]
2. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
Promrat K; McDermott DH; Gonzalez CM; Kleiner DE; Koziol DE; Lessie M; Merrell M; Soza A; Heller T; Ghany M; Park Y; Alter HJ; Hoofnagle JH; Murphy PM; Liang TJ
Gastroenterology; 2003 Feb; 124(2):352-60. PubMed ID: 12557141
[TBL] [Abstract][Full Text] [Related]
3. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source.
Goulding C; McManus R; Murphy A; MacDonald G; Barrett S; Crowe J; Hegarty J; McKiernan S; Kelleher D
Gut; 2005 Aug; 54(8):1157-61. PubMed ID: 15863470
[TBL] [Abstract][Full Text] [Related]
4. Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study.
Nahon P; Sutton A; Rufat P; Faisant C; Simon C; Barget N; Trinchet JC; Beaugrand M; Gattegno L; Charnaux N
Eur J Gastroenterol Hepatol; 2007 May; 19(5):425-31. PubMed ID: 17413295
[TBL] [Abstract][Full Text] [Related]
5. Analysis of CCR5-Delta 32 and CCR2-V64I polymorphisms in a cohort of Spanish HCV patients using real-time polymerase chain reaction and fluorescence resonance energy transfer technologies.
Ruiz-Ferrer M; Barroso N; Antiñolo G; Aguilar-Reina J
J Viral Hepat; 2004 Jul; 11(4):319-23. PubMed ID: 15230854
[TBL] [Abstract][Full Text] [Related]
6. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C.
Wasmuth HE; Werth A; Mueller T; Berg T; Dietrich CG; Geier A; Gartung C; Lorenzen J; Matern S; Lammert F
Hepatology; 2004 Aug; 40(2):327-34. PubMed ID: 15368437
[TBL] [Abstract][Full Text] [Related]
7. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
[TBL] [Abstract][Full Text] [Related]
8. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection.
Hellier S; Frodsham AJ; Hennig BJ; Klenerman P; Knapp S; Ramaley P; Satsangi J; Wright M; Zhang L; Thomas HC; Thursz M; Hill AV
Hepatology; 2003 Dec; 38(6):1468-76. PubMed ID: 14647058
[TBL] [Abstract][Full Text] [Related]
9. Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease.
Huerta C; Alvarez V; Mata IF; Coto E; Ribacoba R; Martínez C; Blázquez M; Guisasola LM; Salvador C; Lahoz CH; Peña J
Neurosci Lett; 2004 Nov; 370(2-3):151-4. PubMed ID: 15488313
[TBL] [Abstract][Full Text] [Related]
10. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection.
Suzuki F; Arase Y; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Takagi K; Satoh J; Kumada H
J Viral Hepat; 2004 May; 11(3):271-6. PubMed ID: 15117331
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C.
Rosen HR; McHutchison JG; Conrad AJ; Lentz JJ; Marousek G; Rose SL; Zaman A; Taylor K; Chou S
Am J Gastroenterol; 2002 Mar; 97(3):714-20. PubMed ID: 11922568
[TBL] [Abstract][Full Text] [Related]
13. [Do polymorphisms of the SDF1 and CCR2b genes modify the course of hepatitis C or HIV/HCV co-infection?].
Woitas RP; Ahlenstiel G; Iwan A; Rockstroh JK; Brackmann HH; Kupfer B; Matz B; Offergeld R; Sauerbruch T; Spengler U
Dtsch Med Wochenschr; 2002 Sep; 127(36):1807-12. PubMed ID: 12215924
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism of low-density lipoprotein receptor did not affect treatment outcome of chronic hepatitis C genotype 3.
Tanwandee T; Pithukpakorn M; Vipatakul N; Charatcharoenwitthaya P; Chainuvati S; Nimanong S; Prachayakul V; Pongprasobchai S; Manatsathit S; Leelakusolvong S; Pausawasdi N; Kachintorn U; Limwongse C; Udompunturak S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S147-53. PubMed ID: 21721440
[TBL] [Abstract][Full Text] [Related]
15. A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C.
Florholmen J; Kristiansen MG; Steigen SE; Sørbye SW; Paulssen EJ; Kvamme JM; Konopski Z; Gutteberg T; Goll R
Clin Microbiol Infect; 2011 Feb; 17(2):204-9. PubMed ID: 20219081
[TBL] [Abstract][Full Text] [Related]
16. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type.
Bogner JR; Lutz B; Klein HG; Pollerer C; Troendle U; Goebel FD
HIV Med; 2004 Jul; 5(4):264-72. PubMed ID: 15236615
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
[TBL] [Abstract][Full Text] [Related]
18. RANTES, MCP-1, CCR2, CCR5, CXCR1 and CXCR4 gene polymorphisms are not associated with the outcome of hepatitis B virus infection: results from a large scale single ethnic population.
Cheong JY; Cho SW; Choi JY; Lee JA; Kim MH; Lee JE; Hahm KB; Kim JH
J Korean Med Sci; 2007 Jun; 22(3):529-35. PubMed ID: 17596666
[TBL] [Abstract][Full Text] [Related]
19. Genetic variations in CC chemokine receptors and hypertension.
Zhang M; Ardlie K; Wacholder S; Welch R; Chanock S; O'Brien TR
Am J Hypertens; 2006 Jan; 19(1):67-72. PubMed ID: 16461193
[TBL] [Abstract][Full Text] [Related]
20. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
